Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fidelity National Information Servcs Inc (FIS) vs Gilead Sciences, Inc. (GILD) Price & Performance

Fidelity National Information Servcs IncTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Fidelity National Information Servcs Inc vs Gilead Sciences, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $42.75 (market cap $21.92B), while Gilead Sciences, Inc. trades at $135.67 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 7.5× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.14%). Which is the better fit depends on your goals.

FISGILD
Market Cap
$21.92B$164.99B
Sector
TechnologyHealth
52-Week High
$72.77$155.80
52-Week Low
$37.72$110.56
Enterprise Value
$42.43B$188.06B
Dividend Yield
4.14%2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fidelity National Information Servcs Inc

FIS trades at $42.77, down slightly on the day, with a bearish technical signal. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, driven by Banking Solutions growth. Recent news highlights the global expansion of its Digital One Commercial platform into the APAC region. Valuation metrics appear attractive with a P/E of 6.57 and a consensus price target of $50.20, though the company lowered its full-year Capital Markets outlook.

The outlook is mixed; strong fundamentals and analyst support suggest upside potential, but near-term price action is weak and execution risks in the Capital Markets segment pose a challenge. The stock offers value but requires monitoring of the revised guidance and competitive pressures in the fintech space.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD